GlycoFi Strengthens Mangement Team
CAMBRIDGE, Mass. and LEBANON, N.H.--(BUSINESS WIRE)--June 2, 2005--GlycoFi, Inc. today announced the appointment of James Posada, Ph.D., MBA to the newly created position of Senior Vice President of Business and Market Development. In this position Dr. Posada will be responsible for all business development and partnering activities, as well as the commercial assessment and positioning of GlycoFi's proprietary compounds. Dr. Posada will report directly to Sylvie Gregoire, Pharm.D., Chief Executive Officer of GlycoFi.
Dr. Posada brings over 15 years combined experience as a business development executive in the pharmaceutical and biotechnology sectors, and basic research scientist. Most recently Dr. Posada was Senior Director of Business Development at Protein Design Labs, Inc., where he was responsible for identifying, evaluating, and negotiating in-licensing opportunities, as well as out-partnering transactions. Prior to that, Dr. Posada was a Manager in the therapeutic proteins division of Eli Lilly & Company, with research management responsibilities, as well as roles in new product planning and product and technology in-licensing. Prior to Eli Lilly, Dr. Posada was an Assistant Professor at the University of Vermont School of Medicine where he ran a basic research laboratory. Dr. Posada holds a Ph.D. in molecular oncology and an MBA, both from the University of Vermont, and a B.S. in biology from Eastern Connecticut State University.
"Jim has an impressive background, which combines experience as a basic scientist with many years of experience in the pharmaceutical industry. GlycoFi will benefit from his broad strategic and transactional experience. We expect Jim to play a key role in developing strategic corporate partnerships and commercializing GlycoFi's proprietary drug molecules," said Sylvie Gregoire CEO of GlycoFi, Inc.
"GlycoFi has developed a breakthrough technology with broad applicability across a majority of therapeutic proteins in development today," said Jim Posada. "I look forward to building the commercial side of the enterprise."
About GlycoFi
GlycoFi, Inc. is a biotechnology company that leverages its pioneering protein production technology to develop, produce and commercialize Next Generation Biotherapeutics(TM), alone and in partnership with other leading biopharmaceutical companies. Sugars, or glycosylation, on the surface of a protein are known to influence critical pharmaceutical properties of therapeutic proteins and monoclonal antibodies. GlycoFi is the leader in the in the area of glycosylation engineering in living systems, and its patented, scaleable technology uniquely allows its partners to create specific human glycosylation variants of any therapeutic glycoprotein. For the first time, GlycoFi and its partners can systematically research the impact of a protein's glycovariants on its pharmaceutical properties, enabling the optimization of biological activity, receptor binding, serum half-life, and potency of the drug candidate, thereby reducing the overall development risk of the project. GlycoFi has several products in research and pre-clinical development and is working on other products in collaboration with leading biopharmaceutical companies. For more information, please visit www.glycofi.com. |
